ArticleSchizophrenia bulletin2026
Altered Vascular and Angiogenic Transcripts in the Neurogenic Niche in Neuroinflammatory-Type Schizophrenia.
Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Investigating changes in the blood-brain barrier in schizophrenia spectrum disorders: design and methodology of a longitudinal dynamic contrast-enhanced MRI study.European archives of psychiatry and clinical neuroscience · 2026Article
- Patient-derived stem cell models of brain endothelial-neuron interactions in early course psychosis.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
background and hypothesisGrowing evidence indicates that vascular processes, including blood-brain barrier (BBB) function and angiogenesis, may be altered in schizophrenia and related to neuroinflammation. The subependymal zone (SEZ) neurogenic niche shows reduced neurogenesis markers in schizophrenia that are more pronounced with neuroinflammation. Since inflammatory neuropathology is related to increased diapedesis-related transcripts, we hypothesize that endothelial cells would be impacted in this neurogenic niche in schizophrenia. STUDY
designWe measured the expression of four BBB-related mRNAs [claudin-5 (CLDN5), occludin (OCLN), platelet endothelial cell adhesion molecule-1 (PECAM1), and tight junction protein 1 (TJP1)] and five angiogenesis-related mRNAs [angiopoietin 1 (ANGPT1), angiopoietin 2 (ANGPT2), vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor receptor 1 (VEGFR1), and TEK receptor tyrosine kinase (TEK)] via quantitative polymerase chain reaction, followed by semi-quantitative immunofluorescence for claudin-5 and collagen-IV protein. We estimated proportions of vascular cells by running cellular deconvolution on previous bulk RNA sequencing data. STUDY
resultsIn high-inflammation schizophrenia, we found increased PECAM1 mRNA, CLDN5 mRNA and claudin-5 protein expression potentially relating to leukocyte trafficking and repair of endothelial tight junctions. The estimated proportion of vascular cells and VEGFA mRNA levels were increased, potentially indicating increased angiogenesis in high-inflammation schizophrenia. Higher VEGFA and CLDN5 mRNA levels were associated with higher expression of markers of immune cell transmigration but lower expression of immature neuron markers, suggesting that vascular dysfunction may impact neurogenesis.
conclusionsThese findings reveal that changes in the BBB and angiogenesis are more severe in high-inflammation schizophrenia and appear to be linked to reduced neurogenesis in the SEZ. This study underscores the importance of inflammation in shaping vascular and neurogenic pathology in schizophrenia, offering potential pathways for future therapeutic exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.